Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Benitec Biopharma ( (BNTC) ).
On November 2, 2025, Benitec Biopharma appointed Dr. Sharon Mates to its Board of Directors, effective November 3, 2025. Dr. Mates, known for her leadership in biotechnology, will serve as a Class I member until the 2026 annual meeting. Her appointment is expected to bolster the company’s strategic direction, particularly in advancing the BB-301 program for OPMD. Additionally, on November 3, 2025, the FDA granted Fast Track Designation to Benitec’s BB-301 for treating OPMD, a significant milestone that could expedite the development and review process of this potentially groundbreaking gene therapy.
The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.
Spark’s Take on BNTC Stock
According to Spark, TipRanks’ AI Analyst, BNTC is a Neutral.
Benitec Biopharma’s stock score is primarily driven by weak financial performance, reflected in large net losses and negative cash flow. The technical outlook is bearish, and valuation concerns arise from a negative P/E ratio. However, the recent positive corporate event provides a glimmer of potential growth, slightly boosting the score.
To see Spark’s full report on BNTC stock, click here.
More about Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focused on developing novel genetic medicines. The company utilizes its proprietary ‘Silence and Replace’ DNA-directed RNA interference platform to create therapies that silence disease-causing genes while delivering replacement genes. Benitec is advancing therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Average Trading Volume: 49,465
Technical Sentiment Signal: Buy
Current Market Cap: $429.5M
For an in-depth examination of BNTC stock, go to TipRanks’ Overview page.